ICAM1 and polycystic ovary syndrome: The cellular adhesion markers have previously been shown to be raised in PCOS (12, 13) and therefore the reductions of ICAM-1, e-selectin and p-selectin that were seen in our study may suggest the mechanism of how exenatide improves the adverse cardiovascular risk profile in PCOS.